1. CDC. Carbapenem-resistant Enterobacteriaceae (CRE) Infection: Clinician FAQs. CDC. 2019. https://www.cdc.gov/hai/organisms/cre/cre-clinicians.html. Accessed 6 Mar 2020.
2. CDC. Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). CDC 2012 PDF. 2012. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. Accessed 6 Mar 2020.
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Guidance for industry. 2017. https://www.fda.gov/downloads/Drugs/Guidances/UCM359184.pdf. Accessed 6 Mar 2020.
4. Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2017;62:1. https://doi.org/10.1128/AAC.01454-17.
5. Aoki T, Yoshizawa H, Yamawaki K, et al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847–68. https://doi.org/10.1016/j.ejmech.2018.06.014(Epub 2018 Jun 8).